MAPK1 and neoplasm: Xia and colleagues employed network pharmacology and experimental validation to unveil that 18β-GRA can decrease the miRNA and protein expression levels of KRAS, ERK1, and ERK2 in AGS cells, targeting inhibition of the MAPK signaling pathway for its anti-tumor effect (Li et al., 2023c).